Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Phase 1
Completed
- Conditions
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaT-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Transformed Mycosis FungoidesRecurrent Transformed Mycosis FungoidesRecurrent Anaplastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Walter Hanel
- Target Recruit Count
- 5
- Registration Number
- NCT04774068
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
News
No news found